China Launches Patent Linkage System to Resolve Drug Patent Disputes Before Market Entry
核心洞察
China's newly implemented drug patent linkage system, known as the Drug Patent Dispute Early Resolution Mechanism, connects marketing authorizations to patent status to resolve disputes between originators and generic manufacturers before market approval.
The system establishes a "Chinese Orange Book" platform where originators can voluntarily list eligible patents within 30 days of receiving market authorization, with generic applicants required to make one of four category statements regarding patent relevance.
Chemical drug applications face a nine-month regulatory approval stay when patent holders challenge Category 4 statements, while the first successful generic challenger receives up to 12 months of market exclusivity.
China has officially launched its drug patent linkage system, marking a significant shift in how pharmaceutical patent disputes are resolved in the world's second-largest pharmaceutical market. The Drug Patent Dispute Early Resolution Mechanism, which came into effect on July 4, 2021, aims to balance protection of innovative drugs with promotion of high-quality generics by resolving patent disputes before generic drugs (搜索) receive market approval.
Chinese Orange Book Establishes Patent Registry Framework
The National Medical Products Administration (搜索) (NMPA) maintains the "Chinese Orange Book," officially known as the Chinese Marketed Drug Patent Information Record Platform. Marketing authorization holders may voluntarily list specific patent information within 30 days of receiving market authorization and must update changes within 30 days of occurrence.
Eligible patents vary by drug type. For chemical drugs (搜索), the system covers active pharmaceutical ingredient (搜索) compound patents, compositions containing APIs, and drug indication patents. Biologics (搜索) can list patents claiming sequence structure of active ingredients, while Traditional Chinese Medicines (搜索) may register composition patents, medicinal herb extract patents, and indication patents.
Notably, the system excludes patents for intermediates, metabolites, crystal forms, manufacturing methods, or testing methods from the Chinese Orange Book. This limitation encourages originators to develop core patents for their drugs rather than relying on peripheral intellectual property protection.
Four-Category Declaration System for Generic Applications
Generic drug applicants must make one of four statements for each applicable patent listed in the Chinese Orange Book when submitting applications to NMPA:
Category 1: No applicable patent is listed in the Chinese Orange Book, allowing NMPA to grant market approval at its discretion after technical review.
Category 2: The applicable listed patent has expired, been invalidated, or the generic applicant has obtained a license from patent holders.
Category 3: The generic applicant commits not to market its drug before the applicable patent expires.
Category 4: The generic applicant believes the applicable patent should be invalidated or that their generic drug does not fall within the patent's protection scope.
The Center for Drug Evaluation (搜索) discloses application information and corresponding declarations within ten working days, while generic applicants must notify marketing authorization holders through registered email addresses.
Regulatory Stay Mechanism for Chemical Drugs
When patent holders challenge Category 4 statements, they have 45 days from NMPA's disclosure of the generic application to file either a lawsuit with Beijing IP Court (搜索) or an opposition with China National Intellectual Property Administration (搜索) (CNIPA). Patent holders must notify NMPA within 15 working days after initiating proceedings.
For chemical drugs (搜索) specifically, NMPA implements a nine-month regulatory approval stay upon receiving notice of judicial or administrative proceedings. This stay affects market approval but does not halt the technical review process. The nine-month period can only be applied once per application.
NMPA resumes the approval process if patent holders cannot obtain favorable decisions within nine months, parties settle the case, the applicable patent is invalidated, or no valid court or CNIPA decision emerges within the stay period.
Market Exclusivity Rewards for Successful Challengers
Generic chemical drug applicants who successfully challenge listed patents through Category 4 statements receive significant market advantages. The first generic to obtain NMPA approval and successfully challenge an applicable patent earns up to 12 months of market exclusivity, provided this period does not exceed the challenged patent's remaining term.
During the exclusivity period, NMPA stays approval of other similar generic chemical drugs (搜索), except for co-challengers. This incentive structure encourages generic manufacturers to challenge weak or invalid patents while providing substantial commercial rewards for successful challenges.
Different Treatment for TCMs and Biosimilars
Traditional Chinese medicines (搜索) with the same name and prescription, along with biosimilar drugs, face different regulatory treatment under the patent linkage system. While these applications can make declarations similar to generic chemical drugs (搜索), they are exempt from the nine-month waiting period.
NMPA may approve TCMs and biosimilars (搜索) for marketing based solely on technical evaluation results. However, products found to fall within patent protection scope according to court rulings or CNIPA decisions must delay market launch until patent expiration.
Implementation Challenges and Future Outlook
The patent linkage system represents a fundamental change in China's pharmaceutical regulatory landscape, requiring both innovative and generic drug companies to reassess their patent prosecution, enforcement, and market access strategies. Several implementation questions remain unresolved, including interpretation of the "double first" concept for market exclusivity designation and definition of co-challengers.
The system's effectiveness will depend on how efficiently courts and CNIPA can handle patent disputes within the prescribed timeframes. The nine-month waiting period may create significant workload burdens for both judicial and administrative bodies, potentially requiring system refinements as implementation experience accumulates.
As China continues developing its pharmaceutical innovation ecosystem, the patent linkage system positions the country alongside other major markets with similar mechanisms, potentially influencing global pharmaceutical companies' patent strategies and market entry decisions in China.